title: Bronchodilator effects of indacaterol and formoterol in patients with COPD.
abstract: BACKGROUND
  Resting inspiratory capacity (IC) reflects static hyperinflation in chronic obstructive pulmonary disease (COPD). This study compared the effects of formoterol and indacaterol, a novel once-daily ultra-long-acting beta(2)-agonist (or ultra-LABA), on resting IC and forced expiratory volume in 1 s (FEV(1)).
  
  
  METHODS
  Thirty patients with COPD (mean FEV(1)/FVC 0.49, mean FEV(1) 56% predicted) each inhaled three treatments (two in randomized sequence followed by open-label formoterol) on separate study days: a single dose of indacaterol 300 microg, matching placebo, and two doses of formoterol 12 microg 12 h apart.
  
  
  RESULTS
  Indacaterol and formoterol increased FEV(1) and IC at all time points relative to placebo (p<0.001). Peak effects on FEV(1) were similar, while indacaterol had a greater effect on peak IC (31% vs 23% from pre-dose; p=0.034). Indacaterol had a greater effect than formoterol on FEV(1) at 8 h (1.47 vs 1.39 L; p=0.014) and 24 h (1.44 vs 1.35 L; p=0.003), and on IC from 4 to 24 h (differences of 0.13-0.19 L; p<0.05). At 24 h, indacaterol and formoterol increased FEV(1) by 17.7% and 7.5%, respectively, from pre-dose.
  
  
  CONCLUSIONS
  This study discriminated between the effects on IC and FEV(1) of once daily indacaterol and twice daily formoterol. The greater effect of indacaterol on IC may translate into improved long-term clinical outcomes.
authors.affiliation: insaf Respiratory Research Institute, Biebricher Allee 34, D-65187 Wiesbaden, Germany. j.beier@insaf-wi.de
authors.forename: J
authors.initials: J
authors.lastname: Beier
authors.forename: K-M
authors.initials: KM
authors.lastname: Beeh
authors.forename: L
authors.initials: L
authors.lastname: Brookman
authors.forename: G
authors.initials: G
authors.lastname: Peachey
authors.forename: A
authors.initials: A
authors.lastname: Hmissi
authors.forename: S
authors.initials: S
authors.lastname: Pascoe
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D000068759:Formoterol Fumarate; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013147:Spirometry; D014797:Vital Capacity
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004983:Ethanolamines; D007189:Indans; D015363:Quinolones; C510790:indacaterol; D000068759:Formoterol Fumarate